Organon & Co. logo

Organon & Co. (OGN)

Market Closed
29 Jul, 20:00
NYSE NYSE
$
10. 14
+0.17
+1.71%
$
2.55B Market Cap
5.74 P/E Ratio
1.12% Div Yield
3,822,100 Volume
4.1 Eps
$ 9.97
Previous Close
Day Range
9.78 10.15
Year Range
8.01 23.1
Want to track OGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 6 days

Summary

OGN closed today higher at $10.14, an increase of 1.71% from yesterday's close, completing a monthly increase of 2.53% or $0.25. Over the past 12 months, OGN stock lost -32.45%.
OGN pays dividends to its shareholders, with the most recent payment made on Jun 12, 2025. The next estimated payment will be in In 1 month on Sep 12, 2025 for a total of $0.02.
The last earnings report, released on Apr 30, 2025, missed the consensus estimates by -1.01%. On average, the company has fell short of earnings expectations by -0.34%, based on the last three reports. The next scheduled earnings report is due on Aug 05, 2025.
The stock of the company had never split.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on NYSE (USD).

OGN Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Organon (OGN) Expected to Beat Earnings Estimates: Should You Buy?

Organon (OGN) Expected to Beat Earnings Estimates: Should You Buy?

Organon (OGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 22 hours ago
Organon (OGN) Outperforms Broader Market: What You Need to Know

Organon (OGN) Outperforms Broader Market: What You Need to Know

In the latest trading session, Organon (OGN) closed at $10.21, marking a +1.39% move from the previous day.

Zacks | 4 days ago
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 6 days ago

Organon & Co. Dividends

Organon & Co. logo
OGN In 1 weeks
Estimated
Quarterly
$0.02 Per Share
Organon & Co. logo
OGN 2 months ago
Paid
Quarterly
$0.02 Per Share
Organon & Co. logo
OGN 5 months ago
Paid
Quarterly
$0.28 Per Share
Organon & Co. logo
OGN 8 months ago
Paid
Quarterly
$0.28 Per Share
Organon & Co. logo
OGN 11 months ago
Paid
Quarterly
$0.28 Per Share
Organon & Co. logo
OGN 10 May 2024
Paid
Quarterly
$0.28 Per Share

Organon & Co. Earnings

29 Oct 2025 (In 3 months) Date
0.94
Cons. EPS
-
EPS
12 Aug 2025 (In 1 week) Date
0.94
Cons. EPS
-
EPS
5 Aug 2025 (In 6 days) Date
0.94
Cons. EPS
-
EPS
30 Apr 2025 Date
1.01
Cons. EPS
-
EPS
13 Feb 2025 Date
0.87
Cons. EPS
0.9
EPS
Organon & Co. logo
OGN In 1 weeks
Estimated
Quarterly
$0.02 Per Share
Organon & Co. logo
OGN 2 months ago
Paid
Quarterly
$0.02 Per Share
Organon & Co. logo
OGN 5 months ago
Paid
Quarterly
$0.28 Per Share
Organon & Co. logo
OGN 8 months ago
Paid
Quarterly
$0.28 Per Share
Organon & Co. logo
OGN 11 months ago
Paid
Quarterly
$0.28 Per Share
Organon & Co. logo
OGN 10 May 2024
Paid
Quarterly
$0.28 Per Share
29 Oct 2025 (In 3 months) Date
0.94
Cons. EPS
-
EPS
12 Aug 2025 (In 1 week) Date
0.94
Cons. EPS
-
EPS
5 Aug 2025 (In 6 days) Date
0.94
Cons. EPS
-
EPS
30 Apr 2025 Date
1.01
Cons. EPS
-
EPS
13 Feb 2025 Date
0.87
Cons. EPS
0.9
EPS

Organon & Co. (OGN) FAQ

What is the stock price today?

The current price is $10.14.

On which exchange is it traded?

Organon & Co. is listed on NYSE.

What is its stock symbol?

The ticker symbol is OGN.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.12%.

What is its market cap?

As of today, the market cap is 2.55B.

What is the earnings per share?

The EPS is 0.94.

When is the next earnings date?

The next earnings report will release on Aug 05, 2025.

Has Organon & Co. ever had a stock split?

No, there has never been a stock split.

Organon & Co. Profile

Drug Manufacturers - General Industry
Healthcare Sector
Kevin Ali CEO
NYSE Exchange
68622V106 Cusip
US Country
10,000 Employees
24 Feb 2025 Last Dividend
- Last Split
2 Jun 2021 IPO Date

Overview

Organon & Co. is a healthcare company focused on innovating and providing a range of health solutions specifically tailored towards women's health needs both in the United States and globally. The company's diverse product offering encompasses a variety of prescription therapies and medical devices. Founded in 2020 and headquartered in Jersey City, New Jersey, Organon & Co. has quickly positioned itself as a key player in women's health, extending its reach through a broad spectrum of contraception and fertility treatments, biosimilars, and other healthcare solutions. Their mission extends to addressing critical areas such as cardiovascular health, respiratory conditions, dermatology, bone health, and non-opioid pain management, catering to a wide demographic. Through its commitment to health innovation, Organon & Co. markets its products to a vast network of stakeholders including drug wholesalers, retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions.

Products and Services

  • Nexplanon: A long-acting reversible contraceptive that offers an effective birth control option.
  • NuvaRing: A monthly vaginal ring designed for convenient contraception.
  • Cerazette: An oral contraceptive pill that helps prevent pregnancy.
  • Marvelon: A daily pill that combines progestin and estrogen to prevent pregnancy.
  • Follistim AQ: Utilized in assisted reproduction to stimulate the development of multiple ovarian follicles.
  • Elonva: An ovarian follicle stimulant for use in assisted reproductive technologies.
  • Ganirelix Acetate Injection: An injectable solution that acts as an antagonist in fertility treatments.
  • Jada: A solution for treating abnormal postpartum uterine bleeding or hemorrhage.
  • Biosimilars Portfolio: Includes immunology products like Brenzys, Renflexis, and Hadlima, along with two oncology products, Ontruzant and Aybintio, offering alternatives to existing biologic medicines.
  • Cholesterol-modifying Medicines: Managed under brands such as Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor to help control cholesterol levels.
  • Cozaar and Hyzaar: Prescribed for the treatment of hypertension.
  • Respiratory Products: Include treatments for asthma under the Singulair, Dulera, Zenhale, and Asmanex brands.
  • Seasonal Allergic Rhinitis Treatments: Products like Singulair, Nasonex, Clarinex, and Aerius are aimed at treating seasonal allergies.
  • Dermatology Products: Including treatments for skin conditions under the Diprosone and Elocon brands.
  • Bone Health Portfolio: Features the Fosamax brand for bone health management.
  • Non-opioid Pain Management Products: Offering solutions like Arcoxia, Diprospan, and Celestone for pain management without the use of opioids.
  • Proscar: Used in the treatment of symptomatic benign prostatic hyperplasia.
  • Propecia: A treatment solution for male pattern hair loss.

Contact Information

Address: 30 Hudson Street
Phone: 551 430 6000